Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies
Sridhar Selvaraj1, Michael Kyba2, Rita C R Perlingeiro3
1Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Abstract:
Pluripotent stem cells (PSCs) represent an attractive cell source for treating muscular dystrophies (MDs) since they easily allow for the generation of large numbers of highly regenerative myogenic progenitors. Using reprogramming technology, patient-specific PSCs have been derived for several types of MDs, and genome editing has allowed correction of mutations, opening the opportunity for their therapeutic application in an autologous transplantation setting. However, there has been limited progress on preclinical studies that validate the therapeutic potential of these gene corrected PSC-derived myogenic progenitors. In this review, we highlight the major research advances, challenges, and future prospects towards the development of PSC-based therapeutics for MDs.
Related Concept Videos
09:11Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
05:54A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
Satellite Stem Cells and Muscular Dystrophy
10:30Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Induced Pluripotent Stem Cells
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

